BTIG analyst Marie Thibault maintained a Buy rating on Atricure (NASDAQ:ATRC) on Monday, setting a price target of $76, which is approximately 5.48% above the present share price of $72.05.
Thibault expects Atricure to post earnings per share (EPS) of -$0.38 for the second quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in Atricure, with an average price target of $83.38.
The analysts price targets range from a high of $102 to a low of $72.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $59.28 million and a net profit of -$15.89 million. The company's market cap is $3.29 billion.
According to TipRanks.com, BTIG analyst Marie Thibault is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 67.7% and a 57.41% success rate.
AtriCure , Inc. engages development, manufacture and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio Frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, Other International, and Total International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in West Chester, OH.